Mesoblast Limited (ASX: MSB)
Australia
· Delayed Price · Currency is AUD | Market Cap | 2.76B |
| Revenue (ttm) | 8.85M |
| Net Income (ttm) | -131.83M |
| Shares Out | 1.14B |
| EPS (ttm) | -0.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,436,822 |
| Open | 2.650 |
| Previous Close | 3.050 |
| Day's Range | 2.365 - 2.750 |
| 52-Week Range | 0.255 - 3.090 |
| Beta | 2.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 24, 2025 |
About Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi... [Read more]
Financial Performance
In 2024, Mesoblast's revenue was $5.90 million, a decrease of -21.32% compared to the previous year's $7.50 million. Losses were -$87.96 million, 7.41% more than in 2023.
Financial numbers in USD Financial StatementsNews
What's Going On With Mesoblast Shares Thursday?
Mesoblast Limited (NASDAQ: MESO) stock is trading higher Thursday after the company announced the U.S. Food and Drug Administration (FDA) approved Ryoncil . The Details: Ryoncil is the first FDA appr...
Mesoblast Finally Gets Its Approval In GVHD: Where Now?
Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating graft-versus-host disease. Read more here.
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
On Wednesday, the FDA approved Mesoblast Limited’s (NASDAQ: MESO) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S . Ryoncil is the only MSC therapy approved in ...
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
On Wednesday, the FDA approved Mesoblast Limited's MESO Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S.
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Sangamo Therapeutics, Inc . (NASDAQ: SGMO) rose sharply in today's pre-market trading . Astellas and Sangamo Therapeutics disclosed Capsid license agreement to deliver genomic medicines for...
Mesoblast shares rocket on FDA approval, but CEO says risks remain
FDA approval for Mesoblast’s cell therapy used to treat children for complications that can occur during bone marrow transplants is a breakthrough for the biotech.
FDA Approves Mesoblast's RYONCIL as First MSC Therapy for Pediatric SR-aGvHD
FDA Approves Mesoblast's RYONCIL as First MSC Therapy for Pediatric SR-aGvHD
Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Admini...
Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.
Mesoblast rises 13% as FDA approves graft-versus-host disease therapy
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-hos...
Mesoblast to join Nasdaq Biotechnology Index
Mesoblast to be Added to Nasdaq Biotechnology Index
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to...
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thu...
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Earlier this year FDA granted REVASCOR both Rare Pe...
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy Phase 3 trial results published in European Journal of Heart F...
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent ...
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
Mesoblast to issue $50M convertible notes for product launch
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a c...
Mesoblast GAAP EPS of -$0.09 beats by $0.63, revenue of $5.9M misses by $1.71M
Mesoblast Limited 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Mesoblast Limited in conjunction with their 2024 Q4 earnings call.
Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and...
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation...